



Attorney Docket No. 9530-3

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Gawad et al.  
Application No.: 10/049,727  
Filed: June 25, 2002  
For: *METHOD FOR DETERMINING PLASMINOGEN ACTIVATOR INHIBITOR*

Confirmation No.: 4559  
Group Art Unit: 1641  
Examiner: Christine E. Foster  
Date: June 12, 2006

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. §1.97(c)**

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(c), before final Office Action or Allowance, whichever is earlier.

In accordance with the requirements of 37 C.F.R. § 1.97(c)(2), a check for the \$180.00 fee specified in 37 C.F.R. § 1.17(p) is enclosed. This amount is believed to be correct. However, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. §1.56 and Section 609 of the MPEP.

Respectfully submitted,

Mary L. Miller  
Registration No. 39,303

Myers Bigel Sibley & Sajovec, P.A.  
P. O. Box 37428  
Raleigh, North Carolina 27627  
Telephone: (919) 854-1400  
Facsimile: (919) 854-1401  
Customer No. 20792

**CERTIFICATION OF EXPRESS MAILING  
UNDER 37 CFR § 1.10**

Express Mail Label No.: EV854926165US

Date of Deposit: June 12, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Tracy Wallace

06/14/2006 CCHAU1 00000024 10049727

02 FC:1806

180.00 OP

Substitute form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	10/049,727
		Filing Date	June 25, 2002
		First Named Inventor	Gawad et al.
		Group Art Unit	1641
		Examiner Name	Christine E. Foster
Sheet 1 of 1	Attorney Docket Number	9530-3	

### U.S. PATENTS AND PATENT PUBLICATIONS

Examiner Initials*		U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	1.	US-4,692,404	Ashihara et al.		09/08/1987
	2.	US-4,318,707	Litman et al.		03/09/1982
	3.	US-5,070,025	Klein et al.		12/03/1991
	4.	US-5,589,401	Hansen et al.		12/31/1996
	5.	US-5,017,009	Schutt et al.		05/21/1991

### U.S. PATENT APPLICATIONS

Examiner Initials*	Cite No.	U.S. Serial No.	Name of Applicant of Cited Document	Date of Filing of Cited Document MM-DD-YYYY
		US-		
		US-		
		US-		

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			

### OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	6.	Seiffert et al. "The Somatomedin B. Domain of Vitronectin" <i>The Journal of Biological Chemistry</i> 269(4):2659-2666 (1994)	
	7.	Declerck et al. "Measurement of Plasminogen Activator Inhibitor 1 in Biologic Fluids With a Murine Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assay" <i>Blood</i> 71(1):220-225 (1998)	
	8.	Bittorf et al. "Alteration of Vitronectin" <i>The Journal of Biological Chemistry</i> 268(33):24838-24846 (1993)	
	9.	Gils et al. "Substrate Behavior of Plasminogen Activator Inhibitor-1 Is Not Associated with a Lack of Insertion of the Reactive Site Loop" <i>Biochemistry</i> 35:7474-7481 (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY


Previously submitted  
on 1-13-02

Substitute form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2



Complete if Known

Application Number	10/049,727
Filing Date	06/25/2002
First Named Inventor	Yahia Gawad
Group Art Unit	1641
Examiner Name	Gailene Gabel
Attorney Docket Number	3477-931

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	5,629,160		Loskutoff et al.	05/13/1997	
	2	5,472,851		Pussard née Constant et al.	12/05/1995	
	3	5,422,245		Nielsen et al.	06/06/95	
	4	5,352,583		Sakata et al.	10/04/1994	
	5	5,102,787		Sasamata et al.	04/07/1992	
	6	4,563,420		Verheijen et al.	01/07/1986	

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	7	Friederich et al., <i>Novel Low-Molecular-Weight Inhibitor of PAI-1 (XR5118) Promotes Endogenous Fibrinolysis and Reduces Postthrombolysis Thrombus Growth in Rabbits</i> , Circulation, Vol. 96, No. 3, August 5, 1997, pp. 916-921	
	8	Ohtani et al., <i>T-686, A Novel Inhibitor of Plasminogen Activator Inhibitor-1, Inhibits Thrombosis Without Impairment of Hemostasis in Rats</i> , European Journal of Pharmacology, Vol. 330, 1997, pp. 151-156	
	9	Nordenhem et al., <i>Plasminogen Activator Inhibitor-1 (PAI-1) Content in Platelets from Healthy Individuals Genotyped for the 4G/5G Polymorphism in the PAI-1 Gene</i> , Scand J. Clin Lab Invest, Vol. 57, 1997, pp. 453-462	
	10	Lang et al., <i>Calcium-Dependent Stabilization of Type I Plasminogen Activator Inhibitor Within Platelet <math>\alpha</math>-Granules</i> , The Journal of Biological Chemistry, Vol. 271, February 2, 1996, pp. 2754-2761	
	11	Sakata et al., <i>Impaired Fibrinolysis Early After Percutaneous Transluminal Coronary Angioplasty Is Associated With Restenosis</i> , American Heart Journal, Vol. 131, No. 1, January 1996, pp. 1-6	
	12	Eitzman et al., <i>Peptide-Mediated Inactivation of Recombinant and Platelet Plasminogen Activator Inhibitor-1 In Vitro</i> , J. Clin. Invest., Vol. 95, May 1995, pp. 2416-2420	
	13	Nieuwenhuizen et al., <i>An Enzyme Immunoassay for the Simultaneous Determination of Active Type-1 Plasminogen Activator Inhibitor (PAI-1), and t<sub>PA</sub>/PAI-1 Complexes</i> , Blood Coagulation and Fibrinolysis, Vol. 6, 1995, pp. 520-526	
	14	Kumik, <i>Circadian Variation in the Efficacy of Tissue-Type Plasminogen Activator</i> , Circulation, Vol. 9, No. 5, pp. 1341-1346	
	15	Hara et al., <i>Plasma Plasminogen Activator Inhibitor-1, Tissue Plasminogen Activator and Serum Lipoprotein(a) After Reperfusion Therapy in Acute Myocardial Infarction: Comparison Between Sequential and Director Percutaneous Transluminal Coronary Angioplasty</i> , Cardiology, Vol. 86, 1995, pp. 407-410	
	16	Stringer et al., <i>Plasminogen Activator Inhibitor-1 Released From Activated Platelets Plays a Key Role in Thrombolysis Resistance: Studies With Thrombi Generated in the Chandler Loop</i> , Arteriosclerosis and Thrombosis, Vol. 14, No. 9, September 1994, pp. 1452-1458	
	17	Gram et al., <i>Multicentre Evaluation of Commercial Kit Methods: Plasminogen Activator Inhibitor Activity, Thrombosis and Haemostasis</i> , Vol. 70, No. 5, 1993, pp. 852-857	
	18	Ogawa et al., <i>Difference in Plasminogen Activator Inhibitor Activity Between Non-Q-Wave Infarction and Q-Wave Infarction</i> , International Journal of Cardiology, Vol. 41, 1993, pp. 201-208	
	19	Sakamoto et al., <i>Association of Patency of the Infarct-Related Coronary Artery With Plasma Levels of Plasminogen Activator Inhibitor Activity in Acute Myocardial Infarction</i> , The American Journal of Cardiology, Vol. 70, No. 3, August 1, 1992, pp. 271-276	
	20	Levi et al., <i>Inhibition of Plasminogen Activator Inhibitor-1 Activity Results in Promotion of Endogenous Thrombolysis and Inhibition of Thrombus Extension in Models of Experimental Thrombosis</i> , Circulation, Vol. 85, No. 1, January 1992, pp. 305-312	
	21	Lijnen et al., <i>On the Reversible Interaction of Plasminogen Activator Inhibitor-1 With Tissue-Type Plasminogen Activator and With Urokinase-Type Plasminogen Activator</i> , The Journal of Biological Chemistry, Vol. 266, No. 7, March 5, 1991, pp. 4041-4044	
	22	Preissner et al., <i>Identification and Partial Characterization of Platelet Vitronectin: Evidence for Complex Formation With Platelet-Derived Plasminogen Activator Inhibitor-1</i> , Blood, Vol. 74, No. 6, November 1, 1989, pp. 1989-1996	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# COPY

Previously submitted  
on 9-13-02

Substitute form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/049,727
				Filing Date	06/25/2002
				First Named Inventor	Yahia Gawad
				Group Art Unit	1641
				Examiner Name	Gailene Gabel
Sheet	2	of	2	Attorney Docket Number	3477-931

	23	Wagner et al., <i>Interaction Between Plasminogen Activator Inhibitor Type 1 (PAI-1) Bound to Fibrin and Either Tissue Type Plasminogen Activator (t-PA) or Urokinase-Type Plasminogen Activator (u-PA)</i> , J. Clin. Invest., Vol. 84, August 1989, pp. 647-655	
	24	Amiral et al., <i>Measurement of tPA and tPA - PAI-1 Complexes by Elisa, Using Monoclonal Antibodies: Clinical Relevance</i> , Thrombosis Research, Supplement VIII: 1988, pp. 99-113	
	25	Francis, Jr. et al., <i>Impaired Fibrinolysis in Coronary Artery Disease</i> , American Heart Journal, Vol. 115, No. 4, April 1988, pp. 776-780	
	26	Urdén et al., <i>Immunological Relationship Between Plasminogen Activator Inhibitors From Different Sources</i> , Thrombosis and Haemostasis, Vol. 57, No. 1, 1987, pp. 29-34	
	27	Verheijen et al., <i>Quantitative Analysis of the Composition of Mixtures of On-Chain and Two-Chain Tissue-Type Plasminogen Activator With a Spectrophotometric Method</i> , Thrombosis Research, Vol. 39, 1985, pp. 281-288	
	28	Hamsten et al., <i>Increased Plasma Levels of Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial Infarction</i> , The New England Journal of Medicine, Vol. 313, No. 25, December 19, 1985, pp. 1557-1563	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.